View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsAugmedix 将来の成長Future 基準チェック /26Augmedixの収益は年間0.9%で減少すると予測されていますが、年間収益は年間20.6%で増加すると予想されています。EPS は年間2.6%で増加すると予想されています。主要情報-0.9%収益成長率2.57%EPS成長率Healthcare Services 収益成長22.3%収益成長率20.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日02 Oct 2024今後の成長に関する最新情報お知らせ • Jun 05Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024Augmedix, Inc. reiterated earnings guidance for the second quarter and full year of 2024. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points.For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million.Major Estimate Revision • May 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$61.1m to US$53.2m. Forecast losses increased from -US$0.52 to -US$0.547 per share. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target down from US$6.10 to US$3.33. Share price fell 48% to US$1.21 over the past week.お知らせ • May 15Augmedix, Inc. Provides Revenue Guidance for the Year 2024Augmedix, Inc. provided revenue guidance for the year 2024. For the year, the company expects to generate revenue of approximately $52 million to $55 million.Price Target Changed • May 14Price target increased by 12% to US$6.83Up from US$6.13, the current price target is an average from 3 analysts. New target price is 497% above last closing price of US$1.15. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.44 last year.Major Estimate Revision • Mar 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.453 to -US$0.523 per share. Revenue forecast unchanged at US$61.3m. Healthcare Services industry in the US expected to see average net income growth of 33% next year. Consensus price target down from US$7.00 to US$6.13. Share price rose 19% to US$3.96 over the past week.お知らせ • Jan 05Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million.すべての更新を表示Recent updatesお知らせ • Oct 04Augmedix's Stock Ceases Trading and to be Delisted from the Nasdaq Stock MarketCommure, Inc. announced that it has completed the acquisition of Augmedix, Inc. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. Upon completion of the transaction, Augmedix's common stock will no longer be publicly listed, and Augmedix will become a privately held company.お知らせ • Oct 03+ 2 more updatesAugmedix, Inc.(NasdaqCM:AUGX) dropped from S&P Global BMI IndexAugmedix, Inc.(NasdaqCM:AUGX) dropped from S&P Global BMI IndexReported Earnings • Aug 13Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$13.7m (up 27% from 2Q 2023). Net loss: US$8.45m (loss widened 68% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Aug 06Augmedix, Inc. to Report Q2, 2024 Results on Aug 12, 2024Augmedix, Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024お知らせ • Jul 21Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million on July 19, 2024. Under the terms of the agreement, Commure will acquire all outstanding shares of Augmedix common stock for a cash consideration of $2.35 per share. The transaction is expected to be funded from Commure’s cash on hand and available liquidity. Upon completion of the transaction, Augmedix’s common stock will no longer be publicly listed, and Augmedix will become a wholly-owned subsidiary of Commure. Augmedix will be required to pay Commure a termination fee of $5.24 million, in case Augmedix terminates the transaction. The transaction is expected to close in late Q3 or early Q4 of 2024. The transaction is subject to approval by Augmedix and Commure stockholders, antitrust approval and the satisfaction of other customary closing conditions. Augmedix’s Board of Directors unanimously approved the transaction. The board of directors of Commure have approved the agreement. Stockholders representing approximately 38% of the Augmedix’s voting power have signed the voting agreements to vote in favor of the transaction. Evercore Group L.L.C. acted as financial advisor to Augmedix and provided fairness opinion to the Augmedix' Board. John M. Rafferty and Michael G. O’Bryan of Morrison & Foerster LLP acted as legal advisor to Augmedix. Marshall P. Shaffer, P.C., Christian A. Atwood, P.C. and Dave Gusella, P.C. of Kirkland & Ellis LLP acted as legal advisor and Morgan Stanley & Co. LLC acted as financial advisor to Commure.分析記事 • Jun 19Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some ScrutinyTo the annoyance of some shareholders, Augmedix, Inc. ( NASDAQ:AUGX ) shares are down a considerable 38% in the last...お知らせ • Jun 05Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024Augmedix, Inc. reiterated earnings guidance for the second quarter and full year of 2024. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points.For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million.お知らせ • May 30Augmedix Appoints Alex Stinard as Chief Clinical AI OfficerAugmedix announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. Dr. Stinard will leverage his clinical and technological acumen to lead the development and expansion of AI solutions that address some of the biggest challenges that impact clinicians and health systems. He will also maintain his current role as the Regional Medical Director of Emergency Medicine at HCA Healthcare in Orlando, Florida. Dr. Stinard’s role will be instrumental as Augmedix continues to improve the patient experience at the point of care, increase productivity by enhancing documentation quality, and reduce the clinician’s cognitive burden of notetaking. Leveraging his forward-thinking approach, Dr. Stinard will spearhead initiatives to elevate clinical workflows and integrate essential clinician judgment to address patient needs comprehensively. With a focus on responsible AI implementation, he will champion real-time support for doctors, enhancing both patient care and clinician experiences.分析記事 • May 21Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?Key Insights Using the 2 Stage Free Cash Flow to Equity, Augmedix fair value estimate is US$1.92 Current share price of...Major Estimate Revision • May 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$61.1m to US$53.2m. Forecast losses increased from -US$0.52 to -US$0.547 per share. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target down from US$6.10 to US$3.33. Share price fell 48% to US$1.21 over the past week.Reported Earnings • May 15First quarter 2024 earnings: EPS exceeds analyst expectationsFirst quarter 2024 results: US$0.12 loss per share. Revenue: US$13.5m (up 40% from 1Q 2023). Net loss: US$6.50m (loss widened 24% from 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US.お知らせ • May 15Augmedix, Inc. Provides Revenue Guidance for the Year 2024Augmedix, Inc. provided revenue guidance for the year 2024. For the year, the company expects to generate revenue of approximately $52 million to $55 million.Price Target Changed • May 14Price target increased by 12% to US$6.83Up from US$6.13, the current price target is an average from 3 analysts. New target price is 497% above last closing price of US$1.15. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.44 last year.Buy Or Sell Opportunity • May 14Now 26% overvaluedOver the last 90 days, the stock has fallen 50% to US$2.34. The fair value is estimated to be US$1.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 43%. Revenue is forecast to grow by 90% in 2 years. Earnings are forecast to decline by 2.7% in the next 2 years.お知らせ • May 01Augmedix, Inc. to Report Q1, 2024 Results on May 13, 2024Augmedix, Inc. announced that they will report Q1, 2024 results After-Market on May 13, 2024分析記事 • Apr 25Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the Augmedix, Inc. ( NASDAQ:AUGX ) share price has dived 29% in the last thirty...お知らせ • Apr 25Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsAugmedix announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry's first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA Healthcare. As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits. Augmedix Go aims to improve the patient experience at the point of care, increase productivity by improving documentation quality, reduce the cognitive burden of note taking by providers, and shorten chart closure time. The clinician feedback and data garnered from the pilot supported Augmedix Go's ability to achieve these objectives. Augmedix utilizes both proprietary fine-tuned large language models (LLMs) and foundationalLLMs, including Google Cloud's MedLM's suite of medically-tuned models. These AI models are utilized across different specialties and sections of the note to deliver high quality medical documentation. Augmedix Go's user interface exposes the principal steps in its note creation process to help instill trust among clinicians.Recent Insider Transactions Derivative • Mar 31Founder notifies of intention to sell stockIan Shakil intends to sell 300k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of March. If the sale is conducted around the recent share price of US$4.04, it would amount to US$1.2m. Since June 2023, Ian has owned 219.66k shares directly. Company insiders have collectively bought US$191k more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • Mar 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.453 to -US$0.523 per share. Revenue forecast unchanged at US$61.3m. Healthcare Services industry in the US expected to see average net income growth of 33% next year. Consensus price target down from US$7.00 to US$6.13. Share price rose 19% to US$3.96 over the past week.Seeking Alpha • Mar 24Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-RewardSummary Augmedix is a company developing an AI-driven medical documentation platform for hospitals and physicians. The company's stock performance has been underwhelming since going public, with a current all-time return of -15%. The company's financials show steady growth but continued losses, and there are concerns about profitability and cash flow generation, making risk-reward unattractive for now. Read the full article on Seeking AlphaReported Earnings • Mar 19Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: US$0.44 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$44.9m (up 45% from FY 2022). Net loss: US$19.2m (loss narrowed 22% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.お知らせ • Mar 12Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix GoAugmedix announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients. New data from survey responses from more than a dozen enterprise and independent healthcare organizations found that clinicians in ambulatory care settings save up to one hour or more per clinic day by using Augmedix Go. Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients. Augmedix Go utilizes a collection of large language models (LLMs) for different note sections, including Google Cloud’s MedLM’s suite of medically-tuned models. This collection of LLMs is used in conjunction with Augmedix’s proprietary natural language processing (NLP) and structured data sets, bringing the most powerful generative AI capabilities to the healthcare industry. By utilizing multiple models that cross-check each other, Augmedix is delivering high quality notes that instill trust among clinicians. Augmedix Go seamlessly integrates with leading EHRs, including Epic, Oracle Cerner, Meditech, and athenahealth, allowing for proper organization of previously unstructured documentation into appropriate clinical data domains. Go uses a problem-based note approach, with note content organized within the History of Present Illness (HPI) and Assessment and Plan (A&P) sections of the patient’s chart. This approach provides an effortless, intuitive note structure for easy review, unlike medical documentation products that lump note content from multiple problems into a single paragraph. As an example, to help oncologists better focus on their patients, Augmedix Go automatically generates the HPI with oncologic history, the interval history with information from the last visit, a comprehensive physical exam including the ECOG (Eastern Cooperative Oncology Group) score, and an A&P that incorporates an impression detailing the status of disease and treatment plans. Clinicians use Augmedix Go to support their individual workflows with features such as additional recordings for multiple interactions across a single patient visit. Behind the scenes, the platform stitches together the recordings to create a comprehensive and structured problem-based or visit-based note, depending on the specialty and organizational preferences. Over half of clinicians use this new feature.お知らせ • Mar 09Augmedix, Inc. to Report Q4, 2023 Results on Mar 18, 2024Augmedix, Inc. announced that they will report Q4, 2023 results After-Market on Mar 18, 2024Buy Or Sell Opportunity • Mar 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 38% to US$3.68. The fair value is estimated to be US$4.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.お知らせ • Feb 13Augmedix Names Tomer Levy as New Senior Vice President of EngineeringAugmedix announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role. Levy brings over 20 years of experience in healthcare information technology. Throughout his career, he has delivered innovative solutions in healthcare IT to large enterprises worldwide. Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare. He is passionate about the adoption of cloud technologies that will define a new benchmark for simplicity, cost-effectiveness, cybersecurity, and leveraging data for improved clinical outcomes. Levy worked closely with the Google Cloud Platform team to build a transformative cloud-native solution for medical imaging that set a new standard for scale, reliability, and efficiency. Levy graduated from the executive MBA program at Tel Aviv University and earned a bachelor’s degree in computer science and economics.Buy Or Sell Opportunity • Jan 23Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to US$5.04. The fair value is estimated to be US$4.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 96% in 2 years. Earnings are forecast to grow by 30% in the next 2 years.お知らせ • Jan 05Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million.お知らせ • Nov 17+ 1 more updateAugmedix, Inc. has filed a Follow-on Equity Offering.Augmedix, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000Price Target Changed • Nov 10Price target increased by 7.0% to US$7.63Up from US$7.13, the current price target is an average from 4 analysts. New target price is 41% above last closing price of US$5.40. Stock is up 278% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.65 last year.分析記事 • Nov 09Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesA week ago, Augmedix, Inc. ( NASDAQ:AUGX ) came out with a strong set of third-quarter numbers that could potentially...Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.097 loss per share (improved from US$0.15 loss in 3Q 2022). Revenue: US$11.8m (up 50% from 3Q 2022). Net loss: US$4.41m (loss narrowed 20% from 3Q 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings have declined by 4.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$16m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding).お知らせ • Oct 31Augmedix, Inc. to Report Q3, 2023 Results on Nov 06, 2023Augmedix, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023Price Target Changed • Oct 23Price target increased by 12% to US$7.13Up from US$6.38, the current price target is an average from 4 analysts. New target price is 36% above last closing price of US$5.23. Stock is up 301% over the past year. The company is forecast to post a net loss per share of US$0.48 next year compared to a net loss per share of US$0.65 last year.Board Change • Oct 09High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rob Faulkner was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 28Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician Controlled Mobile AppAugmedix announced the early access release of the newest product on its platform, Augmedix Go, a clinician-controlled mobile app that uses generative AI to instantaneously create a fully automated draft medical note after each patient visit. Augmedix Go harnesses proprietary natural language processing (NLP), large language models (LLMs), and structured data sets, key components of Augmedix’s tech stack. This powerful technology is utilized in a thoughtful manner to ensure comprehensive and highly accurate medical notes with appropriate guardrails that safeguard against errors. Now available under early access, Augmedix Go allows the clinician to see how the technology works in creating the medical note through a simple and intuitive interface. This innovative product offers a variety of features to support busy healthcare clinicians throughout their clinic day, including summaries of key medical events, reminders of unfinished notes, and flexibility for post-visit dictation and text editing. The technology offers output control through a multimodal interface and can be utilized in both acute and ambulatory care settings. Augmedix Go can be economically adopted and implemented quickly across hospitals and health systems. Augmedix Go allows clinicians immediate access to review, edit and approve their medical notes, and can be integrated into leading electronic health record (EHR) systems.お知らせ • Jul 29Augmedix, Inc. to Report Q2, 2023 Results on Aug 07, 2023Augmedix, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023お知らせ • Jun 27Augmedix, Inc., Annual General Meeting, Jul 13, 2023Augmedix, Inc., Annual General Meeting, Jul 13, 2023, at 09:00 Pacific Standard Time. Location: 111 Sutter Street, Suite 1300, San Francicso California United States Agenda: To elect the three Class III director nominees named in the proxy statement to board of directors; to authorize, for purposes of complying with Nasdaq Listing Rule5635(d), the issuance of shares of common stock, including shares issuable upon the exercise of warrants, pursuant to the Company's Equity Line of Credit (as defined herein) (the ELOC Issuance Proposal); to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the adjustment to the exercise price of the SVB Warrant (as defined herein) (the Warrant Exercise Price Adjustment Proposal); to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2023; and to transact such other business.お知らせ • Jun 13Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product DevelopmentAugmedix announced the establishment of an AI Advisory Council. The healthcare industry's adoption of AI is growing very rapidly and Augmedix is committed to harnessing the power of AI thoughtfully and responsibly to provide its customers with solutions they can trust. The Advisory Council will provide advice and guidance to the Augmedix senior leadership team on matters related to the integration of AI into the Company's product development roadmap. The AI Advisory Council will be led by Joe Marks, Ph.D., who has served as a director of the Company since 2020. Dr. Marks has established himself as a technological innovator in seven different industries over the past 30 years. His areas of expertise include AI, human-computer interaction, and computer graphics. He holds degrees in Applied Mathematics (AB) & Computer Science (SM, PhD) from Harvard University, and has co-authored more than 50 peer-reviewed articles in applied computing. Previously he was the Executive Director of Carnegie Mellon University'sCenter for Machine Learning and Health. Members of the council will include distinguished industry thought leaders from computer science, bioinformatics, digital healthcare, as well as Augmedix customers. These individuals will bring diverse expertise and perspectives from academic institutions, corporate entities from various sectors, healthcare industry associations, as well as civil society organizations associated with AI. The council will hold a variety of responsibilities, including discussing regulatory frameworks, evaluating risks and opportunities for ambient medical documentation product development, reviewing AI applications and algorithms, monitoring and addressing ethical concerns, providing strategic advice and engaging with key stakeholders.お知らせ • Jun 12Joseph W. Marks to Resign from the Augmedix's Board of Directors Effective on the Date of 2023 Annual Meeting of StockholdersOn June 6, 2023, Joseph W. Marks notified the board of directors of Augmedix, Inc. (the “Company”) that he will resign from the Company’s board of directors effective on the date of the Company’s 2023 annual meeting of stockholders. Dr. Marks’ resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Marks plans to continue to advise the Company after his departure from the board by serving as chair of the Company’s AI advisory council, which the Company expects will be formed within the next two to three months.お知らせ • May 13Augmedix, Inc. Provides Revenue Guidance for the Year 2023Augmedix, Inc. provided revenue guidance for the year 2023. Augmedix now expects at least $42 million of revenue in 2023.お知らせ • May 09Augmedix, Inc. to Report Q1, 2023 Results on May 12, 2023Augmedix, Inc. announced that they will report Q1, 2023 results Pre-Market on May 12, 2023お知らせ • Jan 10Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022Augmedix, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. The company's revenue in the fourth quarter of 2022 is expected to be within the guidance range of $8.5 million to $8.6 million.お知らせ • Nov 16Augmedix, Inc. announced delayed 10-Q filingOn 11/15/2022, Augmedix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 08Augmedix, Inc. to Report Q3, 2022 Results on Nov 14, 2022Augmedix, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022お知らせ • Sep 07Augmedix Launches New Service, Augmedix Prep, to Significantly Reduce Physician Chart Prep BurdenAugmedix, Inc. announces the launch of Augmedix Prep, a new service that significantly reduces the burden on medical staff from preparing charts prior to a patient visit. The new service features technology that prepares a patient note structure and content for the physician based on the unique visit type and the patient’s previous medical records. Alleviating this manual task ahead of time, physicians simply review the information prior to seeing the patient, allowing them to enter the visit ready to engage with the patient. Augmedix Prep is designed to address some of the most significant issues facing healthcare providers, including reducing their workload, which can help mitigate clinician burnout and improve satisfaction, as well as allowing time back to focus on patients. Augmedix Prep captures valuable information such as patient demographics, medication changes, up-to-date medical history, imaging, labs and diagnostic results, immunization history and past medical, family, and social history. At its core, chart prep is a time-consuming administrative task that can negatively impact the patient encounter. Augmedix believes that by completing charting work prior to patient encounters, the physician will be better prepared and will offer more time in their schedule for delivering care, resulting in improved patient and provider experience and increasing patient satisfaction.お知らせ • Sep 03Augmedix, Inc. Announces Resignation of Gerard Van Hamel Platerink as DirectorOn September 1, 2022, Mr. Gerard van Hamel Platerink informed the Board of Directors of Augmedix, Inc. of his decision to resign as director and Chairman of the Board, including as a member of its Compensation Committee and Chair of its Nominating and Corporate Governance Committee, effectively as of September 2, 2022. Mr. van Hamel Platerink’s resignation follows his departure from Redmile Group LLC earlier this year.Seeking Alpha • Aug 08Augmedix reports Q2 resultsAugmedix press release (NASDAQ:AUGX): Q2 Revenue of $7.3M misses by $0.03M. Shares +11%. GAAP Net Loss was $7.4 million compared to $4.6 million. EBITDA losses were $6.8 million compared to $3.8 million. Adjusted EBITDA losses were $5.3 million compared to $4.0 million, which excludes the Stock-based compensation expense in both periods, the Loss on extinguishment of the prior debt facility in 2022, and the negotiated reduction of previously invoiced transaction-related expenses, related to the October 2020 transactions, and lease provision write-off in 2021. Cash and restricted cash as of June 30, 2022, was $30.8 million compared to $16.7 million as of June 30, 2021.お知らせ • Aug 04Augmedix - Trio Health - CIIC Announce the Launch of an Innovative PlatformOn Aug. 03, 2022, Trio Health (Trio) and Augmedix, in partnership with the Consortium of Independent Immunology Clinics (CIIC), announced the launch of an innovative platform to automate, standardize, and structure clinical patient data, right from the point of care. The Trio, Augmedix and CIIC physicians' real-world patient ecosystem deliver research-ready clinical insights and real-time disease surveillance for allergy, asthma and immunology care. Augmedix's automated medical documentation technology streams the ambient conversational interaction between CIIC physicians and their patients in real-time and integrates the data captured into Trio's real-world platform to deliver superior and consistent clinical documentation across the network. With the addition of Augmedix's services, Trio's tech-enabled CIIC real-world data registry delivers customizable services to support the entire product lifecycle, including real-time drug surveillance, retrospective and prospective analysis of patient data and accelerated identification of patients for clinical studies. Augmedix and Trio began development of this combined offering in 2019 and are pleased to offer commercial availability to healthcare systems and physician practices. Support for additional specialties is expected later this year.お知らせ • Jul 26Augmedix, Inc. to Report Q2, 2022 Results on Aug 08, 2022Augmedix, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022お知らせ • Apr 26Augmedix, Inc. to Report Q1, 2022 Results on May 09, 2022Augmedix, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022お知らせ • Mar 30Augmedix, Inc. Names William Febbo as New Member to its Board of DirectorsAugmedix, Inc. announced that William Febbo has joined its board of directors, effective March 28, 2022. He is currently Chief Executive Officer and Director of OptimizeRx. Mr. Febbo previously served as Chief Operating Officer of Investment Banking at Merriman Capital and Chief Executive Officer of Digital Capital Network.Seeking Alpha • Jan 21Augmedix: A Splendid Long-Term Investing OpportunityAugmedix drives its revenue growth by reducing burnout of physicians who are highly productive. The company offers physicians medical note documentation service through its Notebuilder tool. Long-term investors can accumulate the company’s shares gradually during pullbacks to maximize their gain.業績と収益の成長予測NasdaqCM:AUGX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202569-25N/AN/A212/31/202453-30N/AN/A26/30/202452-24-18-15N/A3/31/202449-20-21-17N/A12/31/202345-19-19-15N/A9/30/202341-20-21-19N/A6/30/202337-21-22-20N/A3/31/202334-24-20-19N/A12/31/202231-24-18-17N/A9/30/202229-24-19-18N/A6/30/202227-21-21-20N/A3/31/202224-19-18-17N/A12/31/202122-17-19-19N/A9/30/202120-16-18-17N/A6/30/202119-17-14-14N/A3/31/202117-16-15-14N/A12/31/202016-16-15-14N/A9/30/202016-15-16-15N/A6/30/202015-18-18-17N/A3/31/202015-19-18-17N/A12/31/201914-18-15-15N/A12/31/201811-24-20-20N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AUGX今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AUGX今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: AUGX今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AUGXの収益 ( 20.6% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: AUGXの収益 ( 20.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AUGXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/03 11:13終値2024/10/03 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Augmedix, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関William SutherlandBenchmark CompanyYuan ZhiB. Riley Securities, Inc.Elizabeth AndersonEvercore ISI3 その他のアナリストを表示
お知らせ • Jun 05Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024Augmedix, Inc. reiterated earnings guidance for the second quarter and full year of 2024. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points.For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million.
Major Estimate Revision • May 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$61.1m to US$53.2m. Forecast losses increased from -US$0.52 to -US$0.547 per share. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target down from US$6.10 to US$3.33. Share price fell 48% to US$1.21 over the past week.
お知らせ • May 15Augmedix, Inc. Provides Revenue Guidance for the Year 2024Augmedix, Inc. provided revenue guidance for the year 2024. For the year, the company expects to generate revenue of approximately $52 million to $55 million.
Price Target Changed • May 14Price target increased by 12% to US$6.83Up from US$6.13, the current price target is an average from 3 analysts. New target price is 497% above last closing price of US$1.15. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.44 last year.
Major Estimate Revision • Mar 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.453 to -US$0.523 per share. Revenue forecast unchanged at US$61.3m. Healthcare Services industry in the US expected to see average net income growth of 33% next year. Consensus price target down from US$7.00 to US$6.13. Share price rose 19% to US$3.96 over the past week.
お知らせ • Jan 05Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million.
お知らせ • Oct 04Augmedix's Stock Ceases Trading and to be Delisted from the Nasdaq Stock MarketCommure, Inc. announced that it has completed the acquisition of Augmedix, Inc. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. Upon completion of the transaction, Augmedix's common stock will no longer be publicly listed, and Augmedix will become a privately held company.
お知らせ • Oct 03+ 2 more updatesAugmedix, Inc.(NasdaqCM:AUGX) dropped from S&P Global BMI IndexAugmedix, Inc.(NasdaqCM:AUGX) dropped from S&P Global BMI Index
Reported Earnings • Aug 13Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$13.7m (up 27% from 2Q 2023). Net loss: US$8.45m (loss widened 68% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06Augmedix, Inc. to Report Q2, 2024 Results on Aug 12, 2024Augmedix, Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024
お知らせ • Jul 21Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million on July 19, 2024. Under the terms of the agreement, Commure will acquire all outstanding shares of Augmedix common stock for a cash consideration of $2.35 per share. The transaction is expected to be funded from Commure’s cash on hand and available liquidity. Upon completion of the transaction, Augmedix’s common stock will no longer be publicly listed, and Augmedix will become a wholly-owned subsidiary of Commure. Augmedix will be required to pay Commure a termination fee of $5.24 million, in case Augmedix terminates the transaction. The transaction is expected to close in late Q3 or early Q4 of 2024. The transaction is subject to approval by Augmedix and Commure stockholders, antitrust approval and the satisfaction of other customary closing conditions. Augmedix’s Board of Directors unanimously approved the transaction. The board of directors of Commure have approved the agreement. Stockholders representing approximately 38% of the Augmedix’s voting power have signed the voting agreements to vote in favor of the transaction. Evercore Group L.L.C. acted as financial advisor to Augmedix and provided fairness opinion to the Augmedix' Board. John M. Rafferty and Michael G. O’Bryan of Morrison & Foerster LLP acted as legal advisor to Augmedix. Marshall P. Shaffer, P.C., Christian A. Atwood, P.C. and Dave Gusella, P.C. of Kirkland & Ellis LLP acted as legal advisor and Morgan Stanley & Co. LLC acted as financial advisor to Commure.
分析記事 • Jun 19Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some ScrutinyTo the annoyance of some shareholders, Augmedix, Inc. ( NASDAQ:AUGX ) shares are down a considerable 38% in the last...
お知らせ • Jun 05Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024Augmedix, Inc. reiterated earnings guidance for the second quarter and full year of 2024. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points.For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million.
お知らせ • May 30Augmedix Appoints Alex Stinard as Chief Clinical AI OfficerAugmedix announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. Dr. Stinard will leverage his clinical and technological acumen to lead the development and expansion of AI solutions that address some of the biggest challenges that impact clinicians and health systems. He will also maintain his current role as the Regional Medical Director of Emergency Medicine at HCA Healthcare in Orlando, Florida. Dr. Stinard’s role will be instrumental as Augmedix continues to improve the patient experience at the point of care, increase productivity by enhancing documentation quality, and reduce the clinician’s cognitive burden of notetaking. Leveraging his forward-thinking approach, Dr. Stinard will spearhead initiatives to elevate clinical workflows and integrate essential clinician judgment to address patient needs comprehensively. With a focus on responsible AI implementation, he will champion real-time support for doctors, enhancing both patient care and clinician experiences.
分析記事 • May 21Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?Key Insights Using the 2 Stage Free Cash Flow to Equity, Augmedix fair value estimate is US$1.92 Current share price of...
Major Estimate Revision • May 20Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$61.1m to US$53.2m. Forecast losses increased from -US$0.52 to -US$0.547 per share. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target down from US$6.10 to US$3.33. Share price fell 48% to US$1.21 over the past week.
Reported Earnings • May 15First quarter 2024 earnings: EPS exceeds analyst expectationsFirst quarter 2024 results: US$0.12 loss per share. Revenue: US$13.5m (up 40% from 1Q 2023). Net loss: US$6.50m (loss widened 24% from 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US.
お知らせ • May 15Augmedix, Inc. Provides Revenue Guidance for the Year 2024Augmedix, Inc. provided revenue guidance for the year 2024. For the year, the company expects to generate revenue of approximately $52 million to $55 million.
Price Target Changed • May 14Price target increased by 12% to US$6.83Up from US$6.13, the current price target is an average from 3 analysts. New target price is 497% above last closing price of US$1.15. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.44 last year.
Buy Or Sell Opportunity • May 14Now 26% overvaluedOver the last 90 days, the stock has fallen 50% to US$2.34. The fair value is estimated to be US$1.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 43%. Revenue is forecast to grow by 90% in 2 years. Earnings are forecast to decline by 2.7% in the next 2 years.
お知らせ • May 01Augmedix, Inc. to Report Q1, 2024 Results on May 13, 2024Augmedix, Inc. announced that they will report Q1, 2024 results After-Market on May 13, 2024
分析記事 • Apr 25Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the Augmedix, Inc. ( NASDAQ:AUGX ) share price has dived 29% in the last thirty...
お知らせ • Apr 25Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsAugmedix announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry's first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA Healthcare. As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits. Augmedix Go aims to improve the patient experience at the point of care, increase productivity by improving documentation quality, reduce the cognitive burden of note taking by providers, and shorten chart closure time. The clinician feedback and data garnered from the pilot supported Augmedix Go's ability to achieve these objectives. Augmedix utilizes both proprietary fine-tuned large language models (LLMs) and foundationalLLMs, including Google Cloud's MedLM's suite of medically-tuned models. These AI models are utilized across different specialties and sections of the note to deliver high quality medical documentation. Augmedix Go's user interface exposes the principal steps in its note creation process to help instill trust among clinicians.
Recent Insider Transactions Derivative • Mar 31Founder notifies of intention to sell stockIan Shakil intends to sell 300k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of March. If the sale is conducted around the recent share price of US$4.04, it would amount to US$1.2m. Since June 2023, Ian has owned 219.66k shares directly. Company insiders have collectively bought US$191k more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • Mar 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.453 to -US$0.523 per share. Revenue forecast unchanged at US$61.3m. Healthcare Services industry in the US expected to see average net income growth of 33% next year. Consensus price target down from US$7.00 to US$6.13. Share price rose 19% to US$3.96 over the past week.
Seeking Alpha • Mar 24Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-RewardSummary Augmedix is a company developing an AI-driven medical documentation platform for hospitals and physicians. The company's stock performance has been underwhelming since going public, with a current all-time return of -15%. The company's financials show steady growth but continued losses, and there are concerns about profitability and cash flow generation, making risk-reward unattractive for now. Read the full article on Seeking Alpha
Reported Earnings • Mar 19Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: US$0.44 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$44.9m (up 45% from FY 2022). Net loss: US$19.2m (loss narrowed 22% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
お知らせ • Mar 12Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix GoAugmedix announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients. New data from survey responses from more than a dozen enterprise and independent healthcare organizations found that clinicians in ambulatory care settings save up to one hour or more per clinic day by using Augmedix Go. Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients. Augmedix Go utilizes a collection of large language models (LLMs) for different note sections, including Google Cloud’s MedLM’s suite of medically-tuned models. This collection of LLMs is used in conjunction with Augmedix’s proprietary natural language processing (NLP) and structured data sets, bringing the most powerful generative AI capabilities to the healthcare industry. By utilizing multiple models that cross-check each other, Augmedix is delivering high quality notes that instill trust among clinicians. Augmedix Go seamlessly integrates with leading EHRs, including Epic, Oracle Cerner, Meditech, and athenahealth, allowing for proper organization of previously unstructured documentation into appropriate clinical data domains. Go uses a problem-based note approach, with note content organized within the History of Present Illness (HPI) and Assessment and Plan (A&P) sections of the patient’s chart. This approach provides an effortless, intuitive note structure for easy review, unlike medical documentation products that lump note content from multiple problems into a single paragraph. As an example, to help oncologists better focus on their patients, Augmedix Go automatically generates the HPI with oncologic history, the interval history with information from the last visit, a comprehensive physical exam including the ECOG (Eastern Cooperative Oncology Group) score, and an A&P that incorporates an impression detailing the status of disease and treatment plans. Clinicians use Augmedix Go to support their individual workflows with features such as additional recordings for multiple interactions across a single patient visit. Behind the scenes, the platform stitches together the recordings to create a comprehensive and structured problem-based or visit-based note, depending on the specialty and organizational preferences. Over half of clinicians use this new feature.
お知らせ • Mar 09Augmedix, Inc. to Report Q4, 2023 Results on Mar 18, 2024Augmedix, Inc. announced that they will report Q4, 2023 results After-Market on Mar 18, 2024
Buy Or Sell Opportunity • Mar 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 38% to US$3.68. The fair value is estimated to be US$4.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.
お知らせ • Feb 13Augmedix Names Tomer Levy as New Senior Vice President of EngineeringAugmedix announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role. Levy brings over 20 years of experience in healthcare information technology. Throughout his career, he has delivered innovative solutions in healthcare IT to large enterprises worldwide. Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare. He is passionate about the adoption of cloud technologies that will define a new benchmark for simplicity, cost-effectiveness, cybersecurity, and leveraging data for improved clinical outcomes. Levy worked closely with the Google Cloud Platform team to build a transformative cloud-native solution for medical imaging that set a new standard for scale, reliability, and efficiency. Levy graduated from the executive MBA program at Tel Aviv University and earned a bachelor’s degree in computer science and economics.
Buy Or Sell Opportunity • Jan 23Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to US$5.04. The fair value is estimated to be US$4.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 90%. Revenue is forecast to grow by 96% in 2 years. Earnings are forecast to grow by 30% in the next 2 years.
お知らせ • Jan 05Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million.
お知らせ • Nov 17+ 1 more updateAugmedix, Inc. has filed a Follow-on Equity Offering.Augmedix, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000
Price Target Changed • Nov 10Price target increased by 7.0% to US$7.63Up from US$7.13, the current price target is an average from 4 analysts. New target price is 41% above last closing price of US$5.40. Stock is up 278% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.65 last year.
分析記事 • Nov 09Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesA week ago, Augmedix, Inc. ( NASDAQ:AUGX ) came out with a strong set of third-quarter numbers that could potentially...
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.097 loss per share (improved from US$0.15 loss in 3Q 2022). Revenue: US$11.8m (up 50% from 3Q 2022). Net loss: US$4.41m (loss narrowed 20% from 3Q 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings have declined by 4.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$16m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding).
お知らせ • Oct 31Augmedix, Inc. to Report Q3, 2023 Results on Nov 06, 2023Augmedix, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023
Price Target Changed • Oct 23Price target increased by 12% to US$7.13Up from US$6.38, the current price target is an average from 4 analysts. New target price is 36% above last closing price of US$5.23. Stock is up 301% over the past year. The company is forecast to post a net loss per share of US$0.48 next year compared to a net loss per share of US$0.65 last year.
Board Change • Oct 09High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rob Faulkner was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 28Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician Controlled Mobile AppAugmedix announced the early access release of the newest product on its platform, Augmedix Go, a clinician-controlled mobile app that uses generative AI to instantaneously create a fully automated draft medical note after each patient visit. Augmedix Go harnesses proprietary natural language processing (NLP), large language models (LLMs), and structured data sets, key components of Augmedix’s tech stack. This powerful technology is utilized in a thoughtful manner to ensure comprehensive and highly accurate medical notes with appropriate guardrails that safeguard against errors. Now available under early access, Augmedix Go allows the clinician to see how the technology works in creating the medical note through a simple and intuitive interface. This innovative product offers a variety of features to support busy healthcare clinicians throughout their clinic day, including summaries of key medical events, reminders of unfinished notes, and flexibility for post-visit dictation and text editing. The technology offers output control through a multimodal interface and can be utilized in both acute and ambulatory care settings. Augmedix Go can be economically adopted and implemented quickly across hospitals and health systems. Augmedix Go allows clinicians immediate access to review, edit and approve their medical notes, and can be integrated into leading electronic health record (EHR) systems.
お知らせ • Jul 29Augmedix, Inc. to Report Q2, 2023 Results on Aug 07, 2023Augmedix, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023
お知らせ • Jun 27Augmedix, Inc., Annual General Meeting, Jul 13, 2023Augmedix, Inc., Annual General Meeting, Jul 13, 2023, at 09:00 Pacific Standard Time. Location: 111 Sutter Street, Suite 1300, San Francicso California United States Agenda: To elect the three Class III director nominees named in the proxy statement to board of directors; to authorize, for purposes of complying with Nasdaq Listing Rule5635(d), the issuance of shares of common stock, including shares issuable upon the exercise of warrants, pursuant to the Company's Equity Line of Credit (as defined herein) (the ELOC Issuance Proposal); to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the adjustment to the exercise price of the SVB Warrant (as defined herein) (the Warrant Exercise Price Adjustment Proposal); to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2023; and to transact such other business.
お知らせ • Jun 13Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product DevelopmentAugmedix announced the establishment of an AI Advisory Council. The healthcare industry's adoption of AI is growing very rapidly and Augmedix is committed to harnessing the power of AI thoughtfully and responsibly to provide its customers with solutions they can trust. The Advisory Council will provide advice and guidance to the Augmedix senior leadership team on matters related to the integration of AI into the Company's product development roadmap. The AI Advisory Council will be led by Joe Marks, Ph.D., who has served as a director of the Company since 2020. Dr. Marks has established himself as a technological innovator in seven different industries over the past 30 years. His areas of expertise include AI, human-computer interaction, and computer graphics. He holds degrees in Applied Mathematics (AB) & Computer Science (SM, PhD) from Harvard University, and has co-authored more than 50 peer-reviewed articles in applied computing. Previously he was the Executive Director of Carnegie Mellon University'sCenter for Machine Learning and Health. Members of the council will include distinguished industry thought leaders from computer science, bioinformatics, digital healthcare, as well as Augmedix customers. These individuals will bring diverse expertise and perspectives from academic institutions, corporate entities from various sectors, healthcare industry associations, as well as civil society organizations associated with AI. The council will hold a variety of responsibilities, including discussing regulatory frameworks, evaluating risks and opportunities for ambient medical documentation product development, reviewing AI applications and algorithms, monitoring and addressing ethical concerns, providing strategic advice and engaging with key stakeholders.
お知らせ • Jun 12Joseph W. Marks to Resign from the Augmedix's Board of Directors Effective on the Date of 2023 Annual Meeting of StockholdersOn June 6, 2023, Joseph W. Marks notified the board of directors of Augmedix, Inc. (the “Company”) that he will resign from the Company’s board of directors effective on the date of the Company’s 2023 annual meeting of stockholders. Dr. Marks’ resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Marks plans to continue to advise the Company after his departure from the board by serving as chair of the Company’s AI advisory council, which the Company expects will be formed within the next two to three months.
お知らせ • May 13Augmedix, Inc. Provides Revenue Guidance for the Year 2023Augmedix, Inc. provided revenue guidance for the year 2023. Augmedix now expects at least $42 million of revenue in 2023.
お知らせ • May 09Augmedix, Inc. to Report Q1, 2023 Results on May 12, 2023Augmedix, Inc. announced that they will report Q1, 2023 results Pre-Market on May 12, 2023
お知らせ • Jan 10Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022Augmedix, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. The company's revenue in the fourth quarter of 2022 is expected to be within the guidance range of $8.5 million to $8.6 million.
お知らせ • Nov 16Augmedix, Inc. announced delayed 10-Q filingOn 11/15/2022, Augmedix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 08Augmedix, Inc. to Report Q3, 2022 Results on Nov 14, 2022Augmedix, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022
お知らせ • Sep 07Augmedix Launches New Service, Augmedix Prep, to Significantly Reduce Physician Chart Prep BurdenAugmedix, Inc. announces the launch of Augmedix Prep, a new service that significantly reduces the burden on medical staff from preparing charts prior to a patient visit. The new service features technology that prepares a patient note structure and content for the physician based on the unique visit type and the patient’s previous medical records. Alleviating this manual task ahead of time, physicians simply review the information prior to seeing the patient, allowing them to enter the visit ready to engage with the patient. Augmedix Prep is designed to address some of the most significant issues facing healthcare providers, including reducing their workload, which can help mitigate clinician burnout and improve satisfaction, as well as allowing time back to focus on patients. Augmedix Prep captures valuable information such as patient demographics, medication changes, up-to-date medical history, imaging, labs and diagnostic results, immunization history and past medical, family, and social history. At its core, chart prep is a time-consuming administrative task that can negatively impact the patient encounter. Augmedix believes that by completing charting work prior to patient encounters, the physician will be better prepared and will offer more time in their schedule for delivering care, resulting in improved patient and provider experience and increasing patient satisfaction.
お知らせ • Sep 03Augmedix, Inc. Announces Resignation of Gerard Van Hamel Platerink as DirectorOn September 1, 2022, Mr. Gerard van Hamel Platerink informed the Board of Directors of Augmedix, Inc. of his decision to resign as director and Chairman of the Board, including as a member of its Compensation Committee and Chair of its Nominating and Corporate Governance Committee, effectively as of September 2, 2022. Mr. van Hamel Platerink’s resignation follows his departure from Redmile Group LLC earlier this year.
Seeking Alpha • Aug 08Augmedix reports Q2 resultsAugmedix press release (NASDAQ:AUGX): Q2 Revenue of $7.3M misses by $0.03M. Shares +11%. GAAP Net Loss was $7.4 million compared to $4.6 million. EBITDA losses were $6.8 million compared to $3.8 million. Adjusted EBITDA losses were $5.3 million compared to $4.0 million, which excludes the Stock-based compensation expense in both periods, the Loss on extinguishment of the prior debt facility in 2022, and the negotiated reduction of previously invoiced transaction-related expenses, related to the October 2020 transactions, and lease provision write-off in 2021. Cash and restricted cash as of June 30, 2022, was $30.8 million compared to $16.7 million as of June 30, 2021.
お知らせ • Aug 04Augmedix - Trio Health - CIIC Announce the Launch of an Innovative PlatformOn Aug. 03, 2022, Trio Health (Trio) and Augmedix, in partnership with the Consortium of Independent Immunology Clinics (CIIC), announced the launch of an innovative platform to automate, standardize, and structure clinical patient data, right from the point of care. The Trio, Augmedix and CIIC physicians' real-world patient ecosystem deliver research-ready clinical insights and real-time disease surveillance for allergy, asthma and immunology care. Augmedix's automated medical documentation technology streams the ambient conversational interaction between CIIC physicians and their patients in real-time and integrates the data captured into Trio's real-world platform to deliver superior and consistent clinical documentation across the network. With the addition of Augmedix's services, Trio's tech-enabled CIIC real-world data registry delivers customizable services to support the entire product lifecycle, including real-time drug surveillance, retrospective and prospective analysis of patient data and accelerated identification of patients for clinical studies. Augmedix and Trio began development of this combined offering in 2019 and are pleased to offer commercial availability to healthcare systems and physician practices. Support for additional specialties is expected later this year.
お知らせ • Jul 26Augmedix, Inc. to Report Q2, 2022 Results on Aug 08, 2022Augmedix, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022
お知らせ • Apr 26Augmedix, Inc. to Report Q1, 2022 Results on May 09, 2022Augmedix, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022
お知らせ • Mar 30Augmedix, Inc. Names William Febbo as New Member to its Board of DirectorsAugmedix, Inc. announced that William Febbo has joined its board of directors, effective March 28, 2022. He is currently Chief Executive Officer and Director of OptimizeRx. Mr. Febbo previously served as Chief Operating Officer of Investment Banking at Merriman Capital and Chief Executive Officer of Digital Capital Network.
Seeking Alpha • Jan 21Augmedix: A Splendid Long-Term Investing OpportunityAugmedix drives its revenue growth by reducing burnout of physicians who are highly productive. The company offers physicians medical note documentation service through its Notebuilder tool. Long-term investors can accumulate the company’s shares gradually during pullbacks to maximize their gain.